Maybe LL did achieve 50% mortality reduction.
Only
Maybe LL did achieve 50% mortality reduction.
Only reason i think it was more like 25% is because I can't see the FDA letting the trial run if mortality reduction achieved was 50%.
One thousand people die each day in the US. That's 500 per day with a treatment that reduces mortality 50%.
If the LL hit 50 and the FDA said "let it run", it seems to me that the FDA is open to some very severe criticism.
Again I am relying on Dr. Seethamraju comments that the FDA was reviewing the data.
The FDA letting it run on 50 is even more perplexing given the highly unusual facts that the FDA was in there, that Seethamraju knew about it, and Seethamraju revealed the FDA was in there.
The FDA knows, for certain, that Seethamraju is out there.
And the FDA knows, for certain, that Seethamraju will do and say whatever he damn well feels like.
Patterson is a shrinking violet compared to Seethamraju.
So LL is going to hit 50, the FDA is going to let it run, and the FDA expects Seethamraju to sit by quietly and watch?
Seethamraju moved heaven and earth to help his patients when there was zero data, zero preclinical studies, and the FDA did not even believe the drug was relevant.
No way Seethamraju will tolerate not having LL for his patients after it is proven to work!!!
My guess is that the FDA cleared their instructions to CYDY with Seethamraju before the instructions were delivered to CYDY.
Maybe the FDA cajoled Seethamraju with something like, "We have to be true to the mathematics. We have to be sure its not random chance before we treat 10,000 patients."
I can see Seethamraju as susceptible to that argument.
But I have to believe Seethamraju exctracted something from the FDA in return for his agreement.
Seethamraju is certainly not afraid of the FDA.
Question is: Is the FDA afraid of Dr. Seethamraju?
And i think all of this could happen whether mortality reduction is 25% or 50%.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Top 5 Most Recently Viewed Articles
Overview of Recent Sales Trends at Costco Costco Wholesale Corp. (NASDAQ: COST) is currently under the spotlight as its November U.S. core sales reportedly fell short of expectations, hinting at a rare slowing of the company’s ongoing momentum. This dip arrives at a crucial time as consumers gear up for the holiday season, bringing fresh debates regarding overall...
Continue Reading
New Partnership for Luxury Co-Ownership A new era of luxury vacation experiences is upon us as Ember joins with Ascend at Lake Powell to redefine property management and ownership. This collaboration brings forth not just a vacation property but a lifestyle choice that caters to the adventurers at heart. This emerging resort townhome community invites residents to...
Continue Reading
New Developments in Religare's Ownership Battle In a surprising turn of events, India's Religare Enterprises (NSE: RELG) has announced that a U.S. businessman has stepped into the fray with a proposal to secure a 26% stake. This development adds yet another layer of complexity to the ongoing struggle for control over the financial services company, especially following...
Continue Reading
Insulet's Market Performance Insulet (NASDAQ: PODD) has emerged as a standout performer in the stock market arena over the past 15 years. With an annualized return of 23.21%, Insulet has outpaced the broader market by an astonishing 10.41%. Today, the company boasts a market capitalization of approximately $22.62 billion, a testament to its rapid growth and investor...
Continue Reading
UTSA and UT Health San Antonio Merger Overview In a significant step for higher education, UTSA and The University of Texas Health Science Center at San Antonio have merged, resulting in the formation of The University of Texas at San Antonio (UT San Antonio). This new institution emerges as the third-largest public research university in Texas, following prestigious...
Continue Reading
